InvestorsHub Logo

StevenRisk

03/31/22 4:29 PM

#16276 RE: Drugdoctor #16274

Revenues very light compared to estimates. However, margins significantly higher. This really bores great for q1 and beyond.Notice the range is quite wide for revenues.

.17 net income on a $2 stock. Look for this to run hard as this soaks in. A big shout for management on q4. We could very possibly see $1 in earnings per share this year! Surely SCG will really impact q1 and going forward.